<html>
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
   <link rel="stylesheet" type="text/css" href="html_style_eog.txt"/>
<script type="text/javascript">
		function printpage()
		{
		window.print()
		}
		</script></head>
   <body bgcolor='#FFFFFF' onload='javascript: if ((navigator.appName.indexOf("Netscape")!=-1) && parent.leftFrame!=null) parent.leftFrame.location.reload();'><basefont face="Times New Roman, Times New Roman, Times New Roman " size="2">
         <div style="margin-left: +10pt">
            <table width="90%" border="0" rules="none" align="center">
               <colgroup>
                  <col width="90%">
               </colgroup>
               <tr align="center">
                  <td width="20%" colspan="1" rowspan="2" align="left" valign="top">
                     <form><input name="button" type="button" value="   Full Text   " onClick="javascript:document.location.href=('http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=7364725');"></form>
                  </td>
                  <td class="table_data"><b>US 7,364,725 B1</b></td>
                  <td width="20%" colspan="1" rowspan="2" align="right" valign="top">
                     <form><input type="button" value="Print this page" onclick="printpage()"></form>
                  </td>
               </tr>
               <tr align="center">
                  <td colspan="1" class="table_data" style="text-transform: uppercase"><b>Endothelial cells engineered to express or overexpress fibulin-5 and a growth factor</b></td>
               </tr>
               <tr align="center">
                  <td colspan="3" class="table_data"><b> Moshe Flugelman,  Haifa (Israel)</b></td>
               </tr>
               <tr align="center">
                  <td colspan="3" class="table_data"><b>Assigned to  Multi-Gene Vascular Systems Ltd.,  Haifa (Israel)</b></td>
               </tr>
               <tr align="center">
                  <td colspan="3" class="table_data"><b>Filed on Jun.  04, 2002, as Appl. No. 10/163,387.</b></td>
               </tr>
               <tr>
                  <td colspan="3" class="table_data" align="center"><b>Application 10/163387 is a continuation in part of application No. 09/620227, filed on Jul.  20, 2000, abandoned.</b></td>
               </tr>
               <tr align="center">
                  <td colspan="3" class="table_data"><b>This patent is subject to a terminal disclaimer.</b></td>
               </tr>
               <tr align="center">
                  <td colspan="3" class="table_data"><b>Int. Cl. </b><i><b>A01N 63/00</b></i> (2006.01); <i><b>A01N 65/00</b></i> (2006.01); <i><b>A01N 43/04</b></i> (2006.01); <i><b>A61K 31/00</b></i> (2006.01); <i><b>C12N 15/00</b></i> (2006.01)
                  </td>
               </tr>
            </table>
            <table width="90%" border="0" rules="none" align="center">
               <colgroup>
                  <col width="75%">
                  <col width="15%">
               </colgroup>
               <tr align="left">
                  <td class="table_data" align="left"><b>U.S. Cl. </b><b>424&#8212;93.1</b>&nbsp;&nbsp;[435/320.1; 514/44]
                  </td>
                  <td class="table_data" align="right"><b>5 Claims</b></td>
               </tr>
            </table>
            <table width="90%" border="0" rules="none" align="center">
               <colgroup>
                  <col width="90%">
               </colgroup>
               <tr>
                  <td class="table_data" align="center">&nbsp;</td>
               </tr>
               <tr>
                  <td valign="top" class="para_text">1. One or more endothelial cells genetically altered to express one or more cell adhesion factor(s), such that said genetically
                     altered endothelial cells express said one or more cell adhesion factor(s) to an expression level that exceeds that normally
                     produced in said endothelial cells prior to genetic alteration, wherein at least one cell adhesion factor expressed in said
                     endothelial cells is full-length human fibulin-5 polypeptide;
                     <div class="claim_text">and wherein said endothelial cells are genetically altered to express one or more cell proliferation growth factors, such
                        that the genetically altered endothelial cells express said one or more cell growth factors to a expression level that exceeds
                        that normally produced in said endothelial cells prior to genetic alteration.
                     </div>
                  </td>
               </tr>
            </table>
         </div></body>
</html>
